Day: January 2, 2024

Rutherford, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, provides, updates on initial and long-term preclinical testing for the implantable Continuous Blood Glucose Monitor™ (CBGM). The Company announces the successful completion of their first preclinical study of the implantable CBGM. The study’s objective was to assess implant technique and device safety. In addition, a small sample size of sensors was used to determine device functionality. Although not intended to be an accuracy study, the sensor demonstrates a Mean Absolute Relative Difference (MARD) of 8.1% at Day 30 and 4.5% at Day 60. The study was completed with no significant...

CHIHUAHUA, Mexico, Jan. 02, 2024 (GLOBE NEWSWIRE) — GCC, S.A.B. de C.V. (BMV: GCC*), a leading producer of cement and concrete in the United States and Mexico, will host a conference call to review its fourth quarter 2023 earnings results on Wednesday, January 31 at 10:00 a.m. (ET). Earnings results for the quarter ended December 31, 2023, will be released on Tuesday, January 30, after market close. The call will be hosted by Enrique Escalante, CEO, and Mike Strecker, CFO, and can be accessed by dialing +1 (877) 407 0789 or +1 (201) 689 8562 for international calls. The conference ID is 13743114. The presentation and listen-only webcast will be available via the following link. A replay of the webcast will be available the same day at 2:00 p.m. (ET) until February 7 at 11:59 p.m. (ET). The replay can be accessed through this link...

MIGDAL HAEMEK, Israel, Jan. 02, 2024 – Tower Semiconductor (NASDAQ/TASE: TSEM), the leader in high-value analog semiconductor foundry solutions, ), the leading foundry of high-value analog semiconductor solutions, updates following the recent earthquake in Ishikawa Prefecture in Japan, the neighboring Prefecture to where its two Japanese manufacturing facilities are located. The Company expresses relief and gratitude as it reports that all employees are safe. Prioritizing the well-being of its team, Tower remains committed to ensuring their safety during the recovery phase. There was no impact or damage to the buildings and only minor damage to the facilities which had no impact on operations. The dedicated staff and response teams have worked to ensure operational safety and stability. Tools requalification is underway, combined with...

Intermediate Capital Group PLC (“ICG”) (the “Company”) BLOCK LISTING SIX MONTHLY RETURN Date: 2 January 2024Name of applicant: Intermediate Capital Group PLCName of scheme: Save As You Earn Plan 2004Period of return: From: 29 June 2023 To: 29 December 2023Balance of unallotted securities under scheme(s) from previous return: 89,809Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): NilLess: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 18,288Equals: Balance under scheme(s) not yet issued/allotted at end of period: 71,521Name of contact: Andrew LewisTelephone number of contact: +44 (0)20 3545 2000 (FAO Company Secretary)

Equity gains helped to offset liability headwinds from falling interest rates, bringing pension plans to full funding for the first time since the 2008 financial crisis ARLINGTON, Va., Jan. 02, 2024 (GLOBE NEWSWIRE) — The funded status of the nation’s largest corporate defined benefit (DB) pension plans attained an important milestone in 2023 as investment returns outpaced pension liability movements created by falling interest rates, according to an analysis by WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company. WTW examined pension plan data for 358 Fortune 1000 companies that sponsor U.S. DB pension plans and have a December fiscal year-end date. The aggregate pension funded status of these plans at the end of 2023 is estimated to be 100%, two percentage points higher than 98% at the end of 2022. The...

Media Release COPENHAGEN, Denmark; January 2, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco at 11:15 AM PST / 2:15 PM EST / 8:15 PM CET on January 10, 2024. The live and archived webcast of the presentation will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content.  About Genmab Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data...